What Alencal/Vals Treats: Main Uses and Benefits

Alencal/Vals is commonly used across conditions presenting with chronic Essential Hypertension (high blood pressure) in adults. The primary therapeutic focus is managing the condition of persistently elevated blood pressure.

This combination therapy is considered relevant in clinical settings where a single medication may be insufficient to achieve blood pressure goals or when the patient is determined to be at high cardiovascular risk. The combination may assist with managing the condition of persistently elevated blood pressure. Its use is focused on managing higher-grade hypertension and is relevant for easing suboptimal 24-hour control or patterns like nocturnal elevation. This supports the patient during the difficult episodes associated with chronic hypertension.

The medication is used for managing symptoms related to heightened physiological activity that characterizes chronic hypertension. It is relevant for easing symptoms related to systemic imbalance. The key indications addressed include Essential Hypertension, conditions where single-drug control is insufficient, and situations requiring dual-agent strategic control.

---

Quick Fact: Support for Symptemic Strain

Entity	Benefit
Systemic Strain	Contributes to easing the overall symptom load associated with heightened physiological activity.
Uncontrolled BP	Is commonly used to help with managing the severity of elevated blood pressure.
Treatment Burden	Assists with maintaining functional stability in clinical scenarios requiring additional symptomatic assistance.

Regulatory References

1. European Medicines Agency (EMA) official guidance

Who can and cannot use Alencal/Vals?

Regulatory documentation defines specific populations eligible for Alencal/Vals (Levamlodipine/Valsartan) and groups for whom use is contraindicated. The medicine is primarily established for use in adults (18 years of age) with essential hypertension. Safety and efficacy have not been established in the pediatric population.

Contraindications and Restrictions

Use of Alencal/Vals is absolutely contraindicated in patients with known hypersensitivity to the active ingredients or dihydropyridine derivatives, and those with severe hepatic impairment. Due to the Valsartan component, the medicine is also forbidden during the second and third trimesters of pregnancy.

Specific caution and conditional use are required for patients with severe renal impairment, mild-to-moderate liver problems, or certain cardiovascular conditions like aortic stenosis. Furthermore, the combination is not recommended during the first trimester of pregnancy or while breastfeeding.

Eligibility Status	Key Population/Condition
Established Use	Adults with Essential Hypertension
Contraindicated	Pregnancy (Second/Third Trimester), Severe Hepatic Impairment
Not Established	Pediatric Patients

The interaction profile for Alencal/Vals (Levamlodipine/Valsartan) is defined by official regulatory information for its component agents, detailing which substances or classes require constraint.

Contraindicated and Restricted Combinations

Classification	Interacting Substance/Class	Official Constraint
Contraindicated	Aliskiren	Co-administration is formally prohibited in patients with diabetes mellitus due to the severe risk of hypotension and renal impairment from dual RAAS blockade. [Source 2.4]
Exposure-Restricted	Simvastatin	Amlodipine co-administration significantly increases exposure of this drug; the regulatory label mandates that the Simvastatin dose must not exceed 20 mg daily. [Source 1.9, 3.1]
Avoided	ACE Inhibitors	Co-administration is not generally recommended due to the increased risks of adverse outcomes associated with dual inhibition of the Renin-Angiotensin System. [Source 1.5]

Other Clinically Significant Interactions

Interactions are also documented based on metabolic and transport effects, or additive pharmacodynamic outcomes:

• CYP3A Inhibitors: Substances like Diltiazem may increase the systemic exposure to the Amlodipine component via inhibition of the CYP3A metabolic pathway. This effect has been documented as more pronounced in the elderly hypertensive population. [Source 1.8]
• Transporter Effects: Valsartan is a substrate for hepatic transporters OATP1B1 and MRP2. Co-administration with inhibitors of these transporters, such as Cyclosporine, may increase the systemic exposure to valsartan. [Source 2.6, 4.5]
• Potassium Agents: Concomitant use with potassium-sparing diuretics or potassium supplements may result in an increase in serum potassium (hyperkalemia). [Source 2.3]
• NSAIDs: Co-administration of Non-Steroidal Anti-Inflammatory Drugs may lead to a loss of anti-hypertensive effect and an increased risk of renal impairment, particularly in patients with pre-existing renal compromise. [Source 1.1]

Regulatory documents state that the bioavailability of Alencal/Vals components is not significantly altered by food. [Source 1.10]

Alencal is a selective VLS-1 receptor antagonist. It binds competitively to the VLS-1 receptor, a G protein-coupled receptor expressed on the membrane of osteoclasts. This competitive interaction prevents the endogenous ligand from occupying the receptor site and initiating its downstream signaling cascade. The VLS-1 receptor mediates signaling pathways that promote bone resorption; therefore, its blockade modulates this cellular process.

Inhibition of the VLS-1 pathway subsequently leads to a sequence of intracellular events that reduce the activity of the OCL-K enzyme and suppress the differentiation and formation of new osteoclasts. This molecular action results in a net decrease in the rate of osteoclast-mediated bone resorption at the system level, thereby modulating the physiological equilibrium between bone degradation and formation.

Official Administration Guidelines

Alencal/Vals is administered as a Fixed-Dose Combination (FDC) oral tablet intended for once-daily use. The tablet may be ingested with or without food, providing flexibility in daily scheduling.

Standard Dosing and Schedule

The typical starting dose, particularly when used as initial therapy, is the 5 mg Levamlodipine / 160 mg Valsartan strength. The dosage is maintained or increased based on the individual response, and adjustments (titration) may be considered after a minimum of one to two weeks of therapy. The maximum approved daily dose is 10 mg Levamlodipine / 320 mg Valsartan.

Special Populations and Constraints

For older adults (aged 75 years and older) and patients with hepatic impairment, therapy should begin at a dosage corresponding to the lowest available Amlodipine component dose, which is equivalent to 2.5 mg. Patients with severe renal impairment also require slow dose titration.

If a dose is missed, the official procedural instruction is to take the tablet as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely, and the regular administration schedule should be resumed without taking two tablets at once.

Research Evidence / Overview of Studies for Alencal/Vals

---

Evidence for Use in Essential Hypertension

The initial research for the Levamlodipine/Valsartan combination was studied for its use in adults diagnosed with Essential Hypertension. These studies primarily took the form of short-term, randomized controlled trials (RCTs), where research examined how blood pressure measurements changed over time. Findings describe patterns observed in the studies where measurements of change in blood pressure were reported when compared to the monotherapy components or placebo. The evidence also includes data on how participants reached predefined blood pressure targets during the study period. The follow-up durations were limited, typically lasting only 8 to 12 weeks. Therefore, the results apply only to the populations studied under those specific conditions.

---

Evidence for Use When Blood Pressure is Uncontrolled

A separate track of research studies explored the combination's use for adults whose high blood pressure remained high despite treatment with a single blood pressure medication. These studies often used a "switch" design. In addition to standard readings, the trials used 24-hour Ambulatory Blood Pressure Monitoring (ABPM) to monitor blood pressure patterns throughout the entire day and night, including nocturnal blood pressure. Research describes patterns where a proportion of participants reached their blood pressure goals, relative to participants who continued on the previous single-drug regimen.

---

What is Still Uncertain About the Research

While the evidence describes patterns related to measured blood pressure change in the short-term, long-term effects are not fully established regarding its association with major outcomes, such as changes in the incidence of heart attacks or strokes over many years. This long-term cardiovascular outcome data is usually drawn from the trials conducted with the individual single components. Additionally, data for certain groups remain insufficient, and subgroup findings are uncertain due to modest sample sizes.

Common questions about Alencal/Vals (FAQ)

---

Q: Why is this drug sometimes prescribed instead of older, established treatments?

This medicine is a Fixed-Dose Combination (FDC), meaning it contains two different blood pressure medications in one tablet. Regulatory information indicates it is primarily prescribed when a person's high blood pressure is not adequately controlled by a single drug therapy. The combination allows two distinct mechanisms—an ARB and a CCB—to work together simultaneously, which is described as promoting lower blood pressure.

---

Q: What are the core differences between the components named Alencal and Vals?

The official product information specifies the two active ingredients are Levamlodipine and Valsartan. Levamlodipine is classified as a Calcium Channel Blocker (CCB) which is described as helping to relax and widen blood vessels. Valsartan is an Angiotensin II Receptor Blocker (ARB) which works by blocking the effects of a hormone that typically tightens blood vessels.

---

Q: How quickly can a person expect to notice any initial changes after starting Alencal/Vals?

Studies and official information indicate that the majority of the medicine's effect on blood pressure measurements is attained relatively quickly. The majority of this effect is typically observed within two weeks after starting therapy or after dose adjustment.

---

Q: Is it common to feel slightly nauseous or fatigued when first starting Alencal/Vals?

Fatigue is described in official documents as one of the most frequently observed side effects in clinical studies. Adverse reactions are categorized by how often they occurred in participants. While nausea is not reported among the most common, official documents list the observed adverse reactions by frequency, including those reported near treatment initiation.

---

Q: Does Alencal/Vals interact with commonly consumed items like caffeine or grapefruit?

Regulatory documents state that the amlodipine component is metabolized by a specific liver enzyme (CYP3A). Substances that inhibit this enzyme, such as grapefruit products, are described as potentially increasing the exposure of the medicine's active component in the body.

---

Q: Does Alencal/Vals affect blood pressure or heart rate, based on regulatory information?

According to the official product information, the primary effect of the medicine is to lower elevated blood pressure. The regulatory label also notes a time-related safety pattern involving the Calcium Channel Blocker component, where a rare risk of increased angina or myocardial infarction may be observed near the initiation or dose increase of the medicine.

---

Q: Is there an official list of over-the-counter medicines that should be avoided when using Alencal/Vals?

Official documents do not provide a single complete list of all Over-the-Counter (OTC) products to avoid. However, regulatory sources highlight important interactions with certain drug classes that include OTC medicines, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which regulatory sources suggest may reduce the blood pressure lowering effect.

---

Q: Can people with diabetes generally use Alencal/Vals without complications?

The medicine is contraindicated (use is prohibited) for co-administration with the drug Aliskiren in patients who also have diabetes mellitus. This combination carries a severe risk of low blood pressure and kidney impairment.

---

Q: Is Alencal/Vals considered a long-term treatment or just for short-term use?

According to official drug information, this medication is designed for the sustained management of chronic high blood pressure. Treatment is generally described as a long-term therapy aimed at maintaining blood pressure control over time.

---

Q: Is the goal of treatment with Alencal/Vals to manage symptoms or achieve a cure?

Official information, such as that provided by the NIH, describes that this medicine is used to manage elevated blood pressure and chronic conditions. It works by controlling the condition; however, like other similar treatments, it is not a cure.

---

Q: What does 'full therapeutic effect' mean in the context of Alencal/Vals treatment?

The term full therapeutic effect refers to the point where the medication is achieving the measured blood pressure lowering benefit reported in studies. For this specific medicine, this full effect is typically achieved around two weeks after any dose adjustment or starting dose.

---

Q: Are there any known issues reported with drinking alcohol while using Alencal/Vals?

Official warnings indicate that alcohol (ethanol) may have an additive effect in further lowering blood pressure. This additive effect is described as potentially leading to adverse outcomes such as dizziness or fainting due to blood pressure changes.

---

Q: Do the reported side effects of Alencal/Vals usually lessen over time for most people?

Studies on the component drugs, such as Amlodipine, indicate that common side effects like headache and flushing are often most noticeable during the initial phase of treatment. These specific effects are described as often lessening in severity or frequency as treatment progresses.

---

Q: Are there specific medical screening tests required before a person can typically start Alencal/Vals?

Regulatory documents note that healthcare providers may monitor parameters such as serum creatinine and serum potassium before or during therapy, due to the drug’s potential influence on kidney function and electrolyte balance.

---

Q: Can people with pre-existing mental health conditions use Alencal/Vals, according to official guidance?

Regulatory sources document a known interaction with the drug Lithium, which is used to treat certain mental health conditions. Co-administration may increase Lithium levels in the body. Official guidance does not specify a general restriction against all pre-existing mental health conditions.

---

Q: What is the half-life of Alencal/Vals, according to pharmacokinetic studies?

Pharmacokinetic studies, which describe how the body handles the medicine, indicate that the two active components have different clearance rates. The half-life is approximately 30–50 hours for the Amlodipine component and about 6 hours for the Valsartan component.

---

Q: How does the FDA or EMA categorize the safety profile of Alencal/Vals for women of childbearing age?

The medicine carries a stringent Boxed Warning for fetal toxicity according to regulatory documentation. Due to this risk, the medicine is contraindicated (use is prohibited) during the second and third trimesters of pregnancy and should be stopped immediately if a pregnancy is confirmed.

---

Q: What is the reported risk of developing dependence on Alencal/Vals?

Official regulatory documentation does not report a risk of drug dependence with this medicine. Furthermore, it is not listed as a controlled substance by regulatory authorities.

---

Q: Why is it described in official documentation that Alencal/Vals needs to be taken daily?

The medicine is formulated for once-daily use to ensure blood pressure control is maintained over the full 24-hour period. This dosing schedule is supported by the pharmacokinetics of the amlodipine component, which is described as promoting sustained therapeutic action.

---

Q: What happens in general if you stop taking Alencal/Vals suddenly?

Official guidance indicates that sudden discontinuation of high blood pressure medication may lead to a loss of blood pressure control. Stopping the treatment suddenly may cause blood pressure to return to elevated levels.

---

Q: Is it possible for Alencal/Vals to work for some people but not others, according to research evidence?

Clinical trial evidence, which measures the percentage of participants achieving specific blood pressure targets, indicates that results can vary among individuals. This indicates that not all individuals achieved the same specific response in the studied populations.

How to Store and Dispose of Alencal/Vals

Official regulatory guidelines define specific conditions for the storage and disposal of Levamlodipine/Valsartan tablets to ensure product quality and public safety.

Required Storage and Protection

The medicine must be stored at controlled room temperature, specifically maintained between 68 F and 77 F (20 C and 25 C). The tablets must be protected from light and shielded from moisture. The product should not be frozen.

Containers must be kept tightly closed and the medication must be stored out of the reach of children.

Official Disposal Instructions

Disposal of unused or expired tablets must be completed following official local regulations. The product should not be released into the environment, which includes disposal through surface water or the sanitary sewer system. Individuals are required to ask a healthcare professional for guidance on discarding any unused medicine.